RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $26 price target.
RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $26 price target.